Literature DB >> 19377497

Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.

Praneet Kumar1, Gary S Francis, W H Wilson Tang.   

Abstract

Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. Several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19377497     DOI： 10.1038/nrcardio.2009.32

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  56 in total

Review 1.  Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase.

Authors:  Thomas M Lincoln; Xing Wu; Hassan Sellak; Nupur Dey; Chung-Sik Choi
Journal:  Front Biosci       Date:  2006-01-01

2.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.

Authors:  J W Knowles; G Esposito; L Mao; J R Hagaman; J E Fox; O Smithies; H A Rockman; N Maeda
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

4.  Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.

Authors:  Anindita Das; Lei Xi; Rakesh C Kukreja
Journal:  J Biol Chem       Date:  2005-01-24       Impact factor: 5.157

5.  The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.

Authors:  C Sesti; V Florio; E G Johnson; R A Kloner
Journal:  Int J Impot Res       Date:  2006-07-20       Impact factor: 2.896

6.  Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.

Authors:  H Senzaki; C J Smith; G J Juang; T Isoda; S P Mayer; A Ohler; N Paolocci; G F Tomaselli; J M Hare; D A Kass
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

7.  Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure.

Authors:  S D Katz; K Balidemaj; S Homma; H Wu; J Wang; S Maybaum
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

8.  Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure.

Authors:  Gianfranco Piccirillo; Marialuce Nocco; Marco Lionetti; Antonio Moisè; Camilla Naso; Vincenzo Marigliano; Mauro Cacciafesta
Journal:  Am Heart J       Date:  2002-04       Impact factor: 4.749

9.  Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates.

Authors:  M Zakliczynski; M Maruszewski; L Pyka; D Trybunia; P Nadziakiewicz; R Przybylski; M Zembala
Journal:  Transplant Proc       Date:  2007-11       Impact factor: 1.066

10.  Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.

Authors:  Fadi N Salloum; Ramzi A Ockaili; Michael Wittkamp; Vijay R Marwaha; Rakesh C Kukreja
Journal:  J Mol Cell Cardiol       Date:  2006-02-09       Impact factor: 5.000
View more
  8 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension.

Authors:  Ramaswamy Ramchandran; Aarti Raghavan; David Geenen; Miranda Sun; Laura Bach; Qiwei Yang; J Usha Raj
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-08-15       Impact factor: 5.464

Review 3.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 4.  Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

Authors:  Clint L Miller; Chen Yan
Journal:  J Cardiovasc Transl Res       Date:  2010-07-15       Impact factor: 4.132

Review 5.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

6.  Effects of sildenafil and/or muscle derived stem cells on myocardial infarction.

Authors:  Judy Sc Wang; Istvan Kovanecz; Dolores Vernet; Gaby Nolazco; George E Kopchok; Sheryl L Chow; Rodney A White; Nestor F Gonzalez-Cadavid
Journal:  J Transl Med       Date:  2012-08-07       Impact factor: 5.531

7.  T cell costimulation blockade blunts pressure overload-induced heart failure.

Authors:  Marinos Kallikourdis; Elisa Martini; Pierluigi Carullo; Claudia Sardi; Giuliana Roselli; Carolina M Greco; Debora Vignali; Federica Riva; Anne Marie Ormbostad Berre; Tomas O Stølen; Andrea Fumero; Giuseppe Faggian; Elisa Di Pasquale; Leonardo Elia; Cristiano Rumio; Daniele Catalucci; Roberto Papait; Gianluigi Condorelli
Journal:  Nat Commun       Date:  2017-03-06       Impact factor: 14.919

8.  Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats.

Authors:  Latha V Prabhu; Rajalakshmi Rai; Anu V Ranade; Hema Kini; Ashwin Krishnamurthy; Kavitha Leigelin Bernhardt
Journal:  Int J Appl Basic Med Res       Date:  2013-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.